We respect your right to privacy
You can choose not to allow optional cookies (by toggling them below) however, blocking these may impact your experience of the site and the services we are able to offer.
You can find out more about our use of cookies by accessing the Cookie Policy in the footer of this website.

CellAED® headed for UK NHS

World-first Australian-invented personal defibrillator available through NHS Supply Chain

July 2, 2023

The world’s first personal defibrillator, CellAED® will soon be available to UK Government departments, agencies, and services through the NHS Supply Chain.

From 31 July, all NHS broader UK Government, and private sector services that rely on NHS Supply Chain for healthcare equipment, will have access to CellAED® via framework number ITT_1006.

CellAED® is the only AED (automated external defibrillator) offered under the new NHS Supply Chain category of Personal Defibrillator, which was created specifically to accommodate CellAED® in recognition of the new technology’s unique design and features.

CellAED® is designed for its simplicity of use for minimally trained individuals with its proprietary 3 step activation process of Snap Peel StickTM. It can be applied to someone in seconds; the user will snap the device to turn on and start voice instructions, peel to separate the two electrode gel pads, and stick the pads to the bare chest.

The innovation of CellAED® also lies in it being ultra-portable, weighing only 450g and small enough to carry easily, making it available when a sudden cardiac arrest may be witnessed.

Invented by Australian MedTech start-up Rapid Response Revival, CellAED® was created to make defibrillators more accessible and affordable, addressing the low survival rate associated with sudden cardiac arrest.

100,000 people die in the UK every year following cardiac arrest; globally, between 7 and 9 million die annually. This is because cardiac arrest kills quickly – for every minute without treatment, chances of survival decrease by 10 per cent – and survival relies on witnesses to be able to respond immediately with CPR and defibrillation.

More than 80 per cent of these deaths occur in homes and out of hospital, where defibrillators are unlikely to be found due to their high cost of ownership for most households.

“We invented CellAED® so people at home could afford to own a defibrillator. We made it small, lightweight, and easy to use because we want ordinary citizens to be ready to respond if a cardiac arrest occurs near them,” said Rapid Response Revival Founder and CEO, Donovan Casey.

“The availability of CellAED® via NHS Supply Chain is an exceptional achievement. That CellAED® has been accepted as the only personal defibrillator for supply to the agencies of one of the world’s most sophisticated national health services, exemplifies the large-scale adoption opportunities CellAED® was invented for.

“We expect this to result in the adoption of tens of thousands of CellAED® personal defibrillators by NHS Trusts and agencies,” Donovan added.

More than 1,000 UK customers have received their Australian-made CellAED®, which is one of the first places in the world to get access to the personal defibrillator.

CorMed-DX, an Authorised Reseller of CellAED® will be responsible for representing the new ground-breaking technology to purchasers via the NHS Framework.